Zymar, Zymaxid Antitrust Direct Purchaser Class Action Settlement
All persons or entities in the United States who purchased branded Zymar or Zymaxid directly from any of the Defendants from and including June 15, 2010 through December 31, 2017.
Proof of Purchase
Hartig v. Senju, et al.,Case No. 1:14-cv-00719, District Court for the District of Delaware
The lawsuit alleges that Defendants engaged in an unlawful scheme to eliminate or delay generic competition for gatifloxacin ophthalmic solution (generic versions of their branded drugs Zymar and Zymaxid), a drug used to treat eye infections such as bacterial conjunctivitis, in violation of the Sherman Act. Defendants have denied any liability for these claims and have asserted various defenses to the claims.